Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 1, 2010, Pages 215-221

  Deane, Adam M ^a,c   Nguyen, Nam Q ^c   Stevens, Julie E ^b   Fraser, Robert J L ^b,d   Holloway, Richard H ^c   Besanko, Laura K ^d   Burgstad, Carly ^c   Jones, Karen L ^b   Chapman, Marianne J ^a,c   Rayner, Chris K ^b,c   Horowitz, Michael ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 G ORTHO METHYL DEXTRO GLUCOSE; AMIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; TECHNETIUM SULFUR COLLOID TC 99M; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH EMPTYING;

SOLANUM TUBEROSUM;

EID: 75149127635     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1503     Document Type: Article

References (47)

1. Rayner CK, Horowitz M 2005 New management approaches for gastroparesis. Nat Clin Prac 2:454-462
2. Brener W, Hendrix TR, McHugh PR 1983 Regulation of the gastric emptying of glucose. Gastroenterology 85:76-82
3. Fried M, Erlacher U, Schwizer W, Löchner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A 1991 Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101:503-511
4. Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Fried M 1997 Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 41:500-504
5. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA 1985 Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75:1144-1152
6. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, Horowitz M, Feinle-Bisset C 2007 Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol 293:E743-E753
7. Deacon CF 2005 What do we know about the secretion and degradation of incretin hormones? Regul Pept 128:117-124
8. Schirra J, Wank U, Arnold R, Göke B, Katschinski M 2002 Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50:341-348
9. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C 2006 Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 91:1916-1923
10. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
11. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M 2000 Effects of glucagon-like peptide-1(7-36)amide on antro-pyloroduodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46:622-631
12. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M 2008 Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 151:123-129
13. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW 1993 Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36:857-862
14. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M 2004 Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 89:3431-3435
15. Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE 1995 Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med 36:2220-2228
16. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL 2003 Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 88:3829-3834
17. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B 1993 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655
18. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M 1998 Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-1430
19. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
20. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B 2006 Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251
21. Salehi M, Vahl TP, D'Alessio DA 2008 Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 93:4909-4916
22. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Goke B 2009 GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastronterol Motil 21:609-618
23. Schirra J, Göke B 2005 The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128:109-115
24. Horowitz M, Nauck MA 2006 To be or not to be: an incretin or enterogastrone? Gut 55:148-150
25. O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, Wishart JM, Morris HA, Jones KL 2004 Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 47:2208-2214
26. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJ 1983 Gastric emptying in normal subjects: a reproducible technique using a single scintillation camera and computer system. Gut 24:1117-1125
27. Rayner CK, Schwartz MP, van Dam PS, Renooij W, de Smet M, Horowitz M, Smout AJ, Samsom M 2002 Small intestinal glucose absorption and duodenal motility in type 1 diabetes mellitus. Am J Gastroenterol 97:3123-3130
28. Chaikomin R, Wu KL, Doran S, Jones KL, Smout AJ, Renooij W, Holloway RH, Meyer JH, Horowitz M, Rayner CK 2007 Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. Am J Physiol 292:G1099-G1104
29. Matthews JN, Altman DG, Campbell MJ, Royston P 1990 Analysis of serial measurements in medical research. BMJ 300:230-235
30. Bland JM, Altman DG 1995 Calculating correlation coefficients with repeated observations. Part 1. Correlation within subjects. BMJ 310:446
31. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
32. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
33. Imeryüz N, Yeoen BC, Bozkurt A, Copkun T, Villanueva- Peñacarrillo ML, Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.AmJ Physiol 273: G920-G927
34. Willems M, Quartero AO, Numans ME 2001 How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 46:2256-2262
35. Stradley R, Farmer-Bailey P, Pasquini N, Rogers W, Sherding R 1986 Gastric absorption of D-xylose in the rat: its influence on the D-xylose absorption test. J Lab Clin Med 107:10-14
36. Lin HC, Prather C, Fisher RS, Meyer JH, Summers RW, Pimente lM, McCallum RW, Akkermans LM, Loening-Baucke V 2005 Measurement of gastrointestinal transit. Dig Dis Sci 50:989-1004
37. Gentilcore D, Chaikomin R, Jones KL, Russo A, Feinle-Bisset C, Wishart JM, Rayner CK, Horowitz M 2006 Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 91: 2062-2067
38. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G 1993 Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 104:1640-1647
39. Hveem K, Jones KL, Chatterton BE, Horowitz M 1996 Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 38:816-821
40. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M 2007 Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56: 1475-1480
41. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA 2007 The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 92:4165-4171
42. Woerle H, Lindenberger T, Linke R, Foley J, Ligueros-Saylan M, Zhang Y, He HL, Beglinger C, Goeke B, Schirra J, A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes; Program of the American Diabetes Association (ADA) 67th Sessions, Chicago, IL, 2007 (Abstract 0500-P)
43. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
44. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C 1997 Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 113:60-66
45. Meier JJ, Kemmeries G, Holst JJ, Nauck MA 2005 Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54:2212-2218
46. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ 2006 The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol 290:E1118-E1123
47. Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M 1999 Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 22:339-344